House dust mite allergen-specific Immunoglobulin E (HDM-sIgE)

House dust mite (HDM) allergen-specific Immunoglobulin E (IgE) is the primary immunological component responsible for mediating allergic reactions to the species Dermatophagoides pteronyssinus and Dermatophagoides farinae. These IgE antibodies are generated following sensitization to specific mite proteins, such as Der p 1, Der p 2, Der f 1, and Der f 2, which are common triggers for respiratory allergies (PMID: 27087325). Upon allergen exposure, the IgE molecules—which are typically bound to high-affinity FcεRI receptors on mast cells and basophils—undergo cross-linking, triggering the rapid release of inflammatory mediators like histamine and cytokines (PMID: 31002137). This cascade results in the clinical manifestations of allergic rhinitis, atopic dermatitis, and asthma. Therapeutic strategies targeting this pathway include monoclonal antibodies like Omalizumab, which sequester free IgE to prevent receptor binding, and allergen-specific immunotherapy (AIT), which seeks to induce long-term immune tolerance (PMID: 28434687). AIT functions by promoting the production of regulatory T cells and allergen-specific IgG4 antibodies that block IgE-allergen interactions. Monitoring specific IgE levels is crucial for diagnosing HDM allergy and assessing the efficacy of desensitization treatments.

Other names

Der p-specific IgEDer f-specific IgEAnti-HDM IgEHouse dust mite IgEDermatophagoides-specific IgE

Omalizumab binds to the Cε3 domain of IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils (PMID: 24565708). Allergen-specific immunotherapy (AIT) induces immune tolerance by promoting the expansion of regulatory T cells (Tregs) and the production of allergen-specific IgG4 antibodies, which act as blocking antibodies to prevent IgE-mediated allergen recognition (PMID: 28434687).